Figure 3.

Low expression of GLTSCR1 predicts improved prognosis in prostate cancer patients. The Kaplan-Meier method was performed to evaluate the difference in (A) overall and (B) BCR-free survival between high and low expression levels of GLTSCR1 in all patients. The Kaplan-Meier method was performed to evaluate the difference in (C) non-metastatic survival and (D) BCR-free survival between high and low expression levels of GLTSCR1 in non-metastatic patients. BCR, biochemical recurrence; GLTSCR1, glioma tumor suppressor candidate region gene 1.